Market Research Logo

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2015

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia - Pipeline Review, H2 2015’, provides an overview of the Waldenstrom Macroglobulinemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Waldenstrom Macroglobulinemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Waldenstrom Macroglobulinemia Overview
Therapeutics Development
Pipeline Products for Waldenstrom Macroglobulinemia - Overview
Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies
Waldenstrom Macroglobulinemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Waldenstrom Macroglobulinemia - Products under Development by Companies
Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development
AbbVie Inc.
arGEN-X BV
Bayer AG
BeiGene(Beijing) Co.,Ltd
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
Onyx Pharmaceuticals, Inc.
Waldenstrom Macroglobulinemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(INCB-039110+INCB-040093) - Drug Profile
Mechanism of Action
R&D Progress
765IGF-MTX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acalabrutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARGX-110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BGB-3111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-839 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DI-B4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
entospletinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FV-162 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FV-214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMPL-523 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMO-8400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-39110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-40093 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-50465 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ofatumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oprozomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pevonedistat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
spebrutinib besylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Waldenstrom Macroglobulinemia - Recent Pipeline Updates
Waldenstrom Macroglobulinemia - Dormant Projects
Waldenstrom Macroglobulinemia - Discontinued Products
Waldenstrom Macroglobulinemia - Product Development Milestones
Featured News & Press Releases
May 27, 2015: Amgen To present data from Oprozomib study at the 20th Congress of the EHA
Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting
Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop
Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting
Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Genmab A/S, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Idera Pharmaceuticals, Inc., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2015
Waldenstrom Macroglobulinemia - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Waldenstrom Macroglobulinemia Therapeutics - Recent Pipeline Updates, H2 2015
Waldenstrom Macroglobulinemia - Dormant Projects, H2 2015
Waldenstrom Macroglobulinemia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report